n-Lorem Foundation Partners with Hongene Biotech Corporation to Support the Discovery of Personalized ASO Medicines for Nano-rare Patients
April 24 2024 - 9:05AM
Business Wire
n-Lorem, a nonprofit foundation, announced a new partnership
with Hongene Biotech Corporation that supports n-Lorem’s efforts to
discover and provide personalized experimental antisense
oligonucleotide (ASO) medicines to nano-rare disease patients (1 to
30 patients worldwide) for free, for life. As part of its
commitment to n-Lorem and nano-rare patients, Hongene will provide
amidites, compounds essential to developing ASO medicines, to
n-Lorem to offset the costs of developing ASO medicines for up to
20 nano-rare patients.
“In many cases, nano-rare patients will succumb to their disease
without ever having hope of a treatment that will halt their
progressive diseases. At n-Lorem, we can and are changing this for
nano-rare patients today. Our approach enables us to discover and
develop an individualized ASO medicine that targets a nano-rare
patient’s unique mutation, and we do this for free, for life,” said
Stanley T. Crooke, M.D., Ph.D., Chairman, Founder, and CEO, n-Lorem
Foundation. “The need from the nano-rare community is substantial
and we cannot do this alone. Thanks to the generosity of Hongene,
we will be able to discover and evaluate ASO medicines for
nano-rare patients without having to worry about sourcing crucial
amidites. At n-Lorem we are grateful for the support from our
partners as together we work toward making a difference for our
nano-rare patients today.”
Hongene is a global specialist in nucleic acid raw material
supply and CDMO services, committed to providing high-quality,
high-value products with best-in-class lead times. The company
reached out to n-Lorem when it learned of the foundation’s work to
provide experimental ASO medicines for free to nano-rare patients
who need them.
“We are proud to be able to contribute to n-Lorem’s work to help
people living with nano-rare illnesses. At Hongene, we are
dedicated to making nucleic acid medicines universally accessible
for all who need them, including patients in the non-rare disease
community. We are confident that our expertise in the production
and supply of these key raw materials will be a tremendous asset
that will help further the foundation’s mission to bring ASO
medicines to those who need them most,” said Wei Jiang, Founder and
Chief Executive Officer at Hongene.
About Hongene
Hongene is an end-to-end partner for specialist nucleic acid
manufacturing, offering a wide range of products to meet the needs
of the life sciences industry. From standard raw material building
blocks to complex oligonucleotides and mRNA, Hongene consistently
delivers with exceptional quality and value. Through collaborations
Hongene can help unlock the full potential of nucleic acids to
develop life-changing treatments for patients worldwide.
For more information about Hongene and its range of nucleic acid
products, visit the website at www.hongene.com and follow us on
Linkedin.
About n-Lorem
n-Lorem Foundation is a non-profit organization established to
apply the efficiency, versatility, and specificity of antisense
technology to charitably provide experimental antisense
oligonucleotide (ASO) medicines to treat nano-rare patients
diagnosed with diseases that are the result of a single genetic
defect unique to only one or very few individuals. Nano-rare
patients describe a very small group of patients (1-30 worldwide)
who, because of their small numbers, have few if any treatment
options. n-Lorem Foundation was created to provide hope to these
nano-rare patients by developing individualized ASO medicines,
which are short strands of modified DNA that can specifically
target the transcripts of a defective gene to correct the
abnormality. The advantage of experimental ASO medicines is that
they can be developed rapidly, inexpensively and are highly
specific. To date, n-Lorem received over 260 applications for
treatment with more than 120 nano-rare patients approved. n-Lorem
was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and
CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in
1989 and, through his vision and leadership, established the
company as the leader in RNA-targeted therapeutics. Follow us on
Twitter, Facebook, LinkedIn and YouTube.
To learn more about n-Lorem’s mission at www.nlorem.org, and
please consider giving to n-Lorem to bring hope, possibility and
treatment options to these patients and families in need.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240424682378/en/
n-Lorem Contact: Amy Williford, Ph.D. Sr. Director of
Communications amy.williford@nlorem.org